SCHEMBL15075609

SCHEMBL15075609

c1ccc(-c2nc(-c3cccnc3)[nH]c2-c2cccs2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 10/20 0.67
MAPT P10636 9/20 0.64
KDM4E B2RXH2 5/20 0.64
ALDH1A1 P00352 4/20 0.64
HPGD P15428 4/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
CYP1A2 P05177 2/20 0.64
CYP2C19 P33261 2/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2C9 P11712 2/20 0.64
PPARG P37231 1/20 0.64
NCOA2 Q15596 1/20 0.64
NCOA1 Q15788 1/20 0.64
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HTT P42858 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
CYP2D6 P10635 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15075604 0.88 SMPD3 (0.76) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL9736817 0.83 MAPK13 (0.71) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL14059826 0.79 KDM4E (1.00) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL244059 0.77 SMPD3 (0.80) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL30111673 0.76 MAPT (0.67) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL29590048 0.74 CYP2A6 (1.00) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL158705 0.74 CYP2A6 (1.00) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL22291134 0.73 SMPD3 (1.00) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL28402826 0.73 NPY5R (0.88) SMPD3MAPTKDM4EALDH1A1HPGD
SCHEMBL15075610 0.73 MAPK13 (0.77) SMPD3MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165472-A1 HETEROARYLS AND USES THEREOF PIK3R4, VPS4B, PIK3C2A SMPD3 1402/4885MAPT 4467/4885KDM4E 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.